1. Home
  2. NEXT vs URGN Comparison

NEXT vs URGN Comparison

Compare NEXT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

N/A

Current Price

$6.32

Market Cap

2.0B

Sector

Energy

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$40.70

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEXT
URGN
Founded
2010
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
NEXT
URGN
Price
$6.32
$40.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$8.70
★ $60.00
AVG Volume (30 Days)
★ 2.1M
579.2K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,128,000.00
Revenue This Year
N/A
$193.48
Revenue Next Year
N/A
$68.06
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.75
$15.86
52 Week High
$9.24
$50.81

Technical Indicators

Market Signals
Indicator
NEXT
URGN
Relative Strength Index (RSI) 29.80 40.98
Support Level $6.04 $40.94
Resistance Level $6.47 $44.63
Average True Range (ATR) 0.28 1.63
MACD -0.09 -0.23
Stochastic Oscillator 3.27 23.37

Price Performance

Historical Comparison
NEXT
URGN

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: